Psoriatic Arthritis Panel: EULAR 2025
Panelists Drs. Aurelie Najm, Eric Ruderman, Nelly Ziade, Jiha Lee and Jack Cush review highlights of PsA abstracts and sessions presented at the 2025 EULAR meeting in Barcelona, Spain.
Watch video →What's hot!
View all perspectives
What's Hot
Spondyloarthritis Panel: Eular 2025
Panelists: Drs. Peter Nash, Yuz Yusof, Antoni Chan, Adela Castro and Jack Cush.
Watch video →
Steroids, Not JAKi, Are the Real Infection Risk
Dr. David Liew reporting at EULAR 2025 in Barcelona, Spain.
Watch video →
Seronegative Arthritis Breakthroughs
Dr. Janet Pope discusses abstracts POS0015, "Zasocitinib (TAK-279) exhibits high levels of TYK2 inhibition and no inhibition of JAK 1/3 when compared with licensed TYK2 and JAK inhibitors" and POS0016, "Characterization of ORKA-002, a Novel Extended Half-life Monoclonal Antibody Targeting IL-17A/F for the Treatment of Psoriasis and Psoriatic Arthritis", presented at EULAR 2025 in Barcelona, Spain.
Watch video →
JAK Safety Update
Dr. Jonathan Kay offers his perspectives on abstracts POS0150, POS0151, and POS0157 presented at the 2025 EULAR meeting in Barcelona, Spain.
Watch video →
Who/When to Treat Clinically Suspect Arthralgia
Dr. Jack Cush discusses risk stratification in Clinically suspect arthralgia; referencing EULAR2025 abstracts OP0004 (ALTO study) and OP0325 (long term Followup of ARRIA)
Watch video →
Hidradenitis Suppurativa: What Lies Beneath?
Dr. David Liew reports on abstract POS1237 presented at the EULAR 2025 meeting in Barcelona, Spain.
Watch video →
The Value of Kidney Biopsy in Autoimmune Diseases
Dr. Andrea Fava shares his perspective from the EULAR 2025 meeting in Barcelona, Spain.
Watch video →
ICYMI: Introducing Polyrefractory RA: A New Frontier in Difficult-to-Treat RA
At a EULAR 2025 session titled “What makes ‘Difficult-to-treat RA’ so difficult to treat? And what can we do?”, Drs. Paula David and Dennis McGonagle introduced the emerging concept of polyrefractory rheumatoid arthritis (RA), a term now being used to describe a subset of patients who have failed to respond to five or more biologic or targeted synthetic DMARDs. This new classification, derived from recent multinational registry data, represents a significant step in refining our understanding and management of the most treatment-resistant forms of RA.
Read more →
Frequent dosing in PsA: Less or More?
Dr. Eric Ruderman offers his perspective after reviewing abstract POS0016 about less or more frequent dosing in psoriatic arthritis at the 2025 EULAR meeting in Barcelona
Watch video →
Rheumatology RoundUp: EULAR 2025
Featuring Drs. Arthur Kavanaugh and Jack Cush. Abstracts discussed:OP0107OP0325OP0105LB0010POS1051POS1160POS0017POS0173LB0005
Watch video →
New IL-17 Inhibition New Molecular Constructs
Dr. Philip Mease offers his perspective from the 2025 EULAR meeting in Barcelona, Spain.
Watch video →
Rituximab - Super Responders Exist in SLE
Dr. Yuz Yusof reports on abstract POS0325 presented at the 2025 EULAR meeting in Barcelona.
Watch video →
IL-17 Inhibitors for Axial Spondyloarthritis
Dr. Philip Mease discusses take-home messages from the IL-17 in axSpA data presented at the 2025 EULAR meeting in Barcelona, Spain.
Watch video →
IL-17 Inhibitors in Psoriatic Arthritis
Dr. Philip Mease offers his perspective on IL-17 inhibitors in psoriatic arthritis presented at the 2025 EULAR meeting in Barcelona, Spain.
Watch video →
What we need in very early arthritis
It's easy to think that in our current world that we've done it all for rheumatoid arthritis, that there's nothing left to be done after b/tsDMARDs have become relatively widespread and accessible. If we aren’t satisfied that we’ve done all we can for our RA patients, how can we make their treatment and their lives better?
Read more →
Trends and Innovations from Barcelona (6.20.2025)
Dr. Jack Cush reviews highlights, trends and novel studies from EULAR 2025 in Barcelona from last week.
Read more →
All Rheumatoid Arthritis is Not the Same
Dr. Jonathan Kay reviews abstracts OP0323 and OP0328 from the EULAR 2025 meeting in Barcelona, Spain.
Watch video →
Aurelie Najm AurelieRheumo
10 months 3 weeks ago
APEX study Ph3 RCT Guselkumab
In BioNaive active PsA w/ erosions>=2
wk 24
ACR20 GUS Q4W 67% Q8W 68% vs PBO 47%
Less Rx progression in both Q4W & Q8W vs. PBO
#EULAR2025 @RheumNow LB0010 https://t.co/OVDWWECtOZ
Mrinalini Dey DrMiniDey
10 months 3 weeks ago
💉Early results from a dose-escalation trial of novel CD19xCD3xCD28 trispecific antibody (CC312) in refractory #SLE show no ICANS or ≥G2 CRS, rapid B cell depletion & 100% SRI-4 response (n=5).
@RheumNow #EULAR2025 #LB0007 #CART
Md Yuzaiful Md Yusof Yuz6Yusof
10 months 3 weeks ago
#EULAR2025 Abstr#LB0005 Phase IIb RCT in moderate #Sjogren reported significant reduction in ESSDAI at WK24 from BL in HCQ-Leflunomide vs PBO. CRESS & STAR improved. No significant difference in UWS, Schirmer, & ESSPRI. Future work: cohort of high symptom burden @RheumNow
Aurelie Najm AurelieRheumo
10 months 3 weeks ago
The relation between RA, comorbidities and presenteism
NRAS survey 891 RA pts
75% had at least one comorbidity
Absenteeism more likely if
One OR = 1.68 or Two OR = 2.26 comorbid conditions
In particular
Anxiety OR = 2.39
Depression OR = 1.75
Osteoarthritis OR = 1.85
Back
Nelly ZIADE 🍀 Nellziade
10 months 3 weeks ago
The transformative potential of integrating ePROMs into AI care pathways
🔺️Study by Dr Antoni Chan et al. achieved a new-to-followup ratio of 1:2.5 outperforming the national average of 1:4.2
🔺️Without losing contact with pts
@synovialjoints
POS1271
#EULAR2025
@RheumNow https://t.co/z3jO3ADHR1
Mrinalini Dey DrMiniDey
10 months 3 weeks ago
🦵🏻SAP-001, a novel uricosuric targeting a non-URAT1 renal transporter, lowered sUA <6 mg/dL in up to 79% of patients with refractory #gout on b/g xanthine oxidase inhibitor. >50% on 60 mg/day reached sUA <3 mg/dL.
💊Potential new oral ULT option.
@RheumNow #EULAR2025 #LB0008 https://t.co/dfY1V5sHSh
Aurelie Najm AurelieRheumo
10 months 3 weeks ago
Why do Rheumatologists shift to private practice? Are there gender based differences?
A survey of 100+ European rheumatologists
Female 🚺 rheumatologists:
Leave hospital earlier
At a lower hierarchical level
Reasons for leaving:
nightshifts
unfair promotion decisions
Nelly ZIADE 🍀 Nellziade
10 months 3 weeks ago
EULAR PtC for definition of #TR Trt Refractory) #Psoriatic_Arthritis
#D2M
1️⃣ Failure >= 2 b/tsDMARDs
2️⃣ Problematic
3️⃣ Evidence of persistent dis
+
4️⃣ Exclude drivers like comorbidities & psychosocial factors
🔺️Exclude failure due to Side Effets/CI
#EULAR2025
@RheumNow https://t.co/ULD2Xe6p6A
Bella Mehta bella_mehta
10 months 3 weeks ago
Will climate change impact rheumatological care?
#EULAR2025 @rheumnow
Especially larger cities are are affected more.
Need to worry about comorbidities https://t.co/KhTyAssGeI
Nelly ZIADE 🍀 Nellziade
10 months 3 weeks ago
Imagine #Barcelona with an additional 8 degrees in summer 🔥 🔥🔥
Session: Disaster Medicine - Impact of climate change, heat, and global insecurity
#EULAR2025
@RheumNow https://t.co/1TqlBJtoZD
Bella Mehta bella_mehta
10 months 3 weeks ago
RA is worst with temperature rising/ climate change.
However SpA has the opposite effect!
Climate change session at #EULAR2025 @RheumNow https://t.co/eKVXnfdEzD
Adela Castro AdelaCastro222
10 months 3 weeks ago
Tips for Dx RP:
1. Suspect the dx and recognize chondritis.
2. Rule out mimickers
3.Tracheal involvement shows swelling>stenosis (helps ≠from GCA)
4. CV, heme, derm manifestations 🧐VEXAS.
5. biopsy not useful unless ≠ from GCA.
Fantastic session by @Lupusreference https://t.co/W4DgfeRULF
Md Yuzaiful Md Yusof Yuz6Yusof
10 months 3 weeks ago
#EULAR2025 Abstr#POS1155 Fatigue remains a management challenge in #SLE. Consistent with other endpoints achieved, Dapirolizumab+SOC improved fatigue (FACIT-Fatigue & FATIGUE-PRO) over PBO+SOC in a Phase 3 RCT @RheumNow https://t.co/rYujy2YjBl
Aurelie Najm AurelieRheumo
10 months 3 weeks ago
What do we do when we see Rx signed of CPPD in RA pts? Do these pts have different trajectory?
Rx Retro study 388 patients RA
18% at least one sign CPPD
ns diff between seeonegative and seropositive pts
RA+CPPD group was
-older
-higher comorbidity score
-more likely to be https://t.co/DaW5DZoDzF
Bella Mehta bella_mehta
10 months 3 weeks ago
Vector borne diseases that result in arthritis will rise with climate change/ flooding risk
- Chikungunya
- Dengue
- Zika
- West-Nile Virus
@RheumNow #EULAR2025 https://t.co/HtHyADsOSX
Poster Hall